Eurofins Genomics Signs Contract to Supply Oligonucleotides to Swedish Research Councils

March 1st, 2016

Eurofins Genomics, a global leader in bioanalytical testing announces their new, state-of-the-art manufacturing and services facility in Louisville, KY.  The large, 65,800 ft2 (6.113 m2) facility functions as their central laboratory in North America, focusing on the production of DNA and RNA synthesis and synthetic gene synthesis, and genomics services including DNA sequencing, synthetic biology, and next generation sequencing. 
As a leader in analytical lab technology, Eurofins continues to expand its global infrastructure of advanced laboratories. Last year alone, Eurofins made 21 strategic acquisitions covering over 350,000 m2.  Since 2005, Eurofins has invested over $800,000,000 dollars for 115 new facilities, spanning 39 countries.  However, the Louisville, KY facility marks the newest and most advanced genomics facility in the world.  As a multi-functional hub, it will contain additional Eurofins divisions such as Microbiology Laboratories and Food Testing, which fosters diversity, creativity, and synergy between scientific applications.
The company will introduce new, proprietary synthesis technology in the new facility which will lead to increased quality and reliability in its oligonucleotides.   Quality standards implemented during construction are already among the highest in the industry and supported by several internationally recognized certifications such as ISO 9001:2008, ISO 13485: 2003 and an FDA certification for GMP production. 
“Eurofins has always been committed to quality, technology, and advancing the interests and research of scientists around the globe.  We are proud to open our newest competence center in Louisville, KY, the most advanced facility of its kind in the world.”